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Background: Pelvic exenteration for locally advanced rectal cancer (LARC) and locally recurrent rectal
cancer (LRRC) is technically challenging but increasingly performed in specialist centres. The aim of this
study was to compare outcomes of exenteration over time.
Methods: This was a multicentre retrospective study of patients who underwent exenteration for LARC
and LRRC between 2004 and 2015. Surgical outcomes, including rate of bone resection, flap reconstruc-
tion, margin status and transfusion rates, were examined. Outcomes between higher- and lower-volume
centres were also evaluated.
Results: Some 2472 patients underwent pelvic exenteration for LARC and LRRC across 26 institutions.
For LARC, rates of bone resection or flap reconstruction increased from 2004 to 2015, from 3⋅5 to 12⋅8
per cent, and from 12⋅0 to 29⋅4 per cent respectively. Fewer units of intraoperative blood were transfused
over this interval (median 4 to 2units; P= 0⋅040). Subgroup analysis showed that bone resection and
flap reconstruction rates increased in lower- and higher-volume centres. R0 resection rates significantly
increased in low-volume centres but not in high-volume centres over time (low-volume: from 62⋅5 to
80⋅0 per cent, P= 0⋅001; high-volume: from 83⋅5 to 88⋅4 per cent, P= 0⋅660). For LRRC, no significant
trends over time were observed for bone resection or flap reconstruction rates. The median number of
units of intraoperative blood transfused decreased from 5 to 2⋅5units (P< 0⋅001). R0 resection rates did
not increase in either low-volume (from 51⋅7 to 60⋅4 per cent; P= 0⋅610) or higher-volume (from 48⋅6 to
65⋅5 per cent; P=0⋅100) centres. No significant differences in length of hospital stay, 30-day complication,
reintervention or mortality rates were observed over time.
Conclusion: Radical resection, bone resection and flap reconstruction rates were performed more
frequently over time, while transfusion requirements decreased.
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Introduction
Advanced rectal cancer surgery is technically challenging1.
As outcomes correlate directly with hospital volume2,
there is a trend towards centralization of rectal cancer
resections3,4. There is no consensus, however, on the
minimum quota for managing complex advanced rectal
cancer. Overall referral patterns have remained largely
unchanged5, as many patients prefer to be treated in
their community, even though outcomes may be better in
large-volume centres6.
Several studies4,7,8 have reported decreased morbidity
and mortality for particular complex surgical procedures
when performed by surgeons undertaking higher vol-
umes, based on the simplistic premise that ‘practice makes
perfect’9. Thus, experienced surgeons are thought to be
more proficient in terms of technical skill and management
of complications7. Surgeons’ annual volume, rather than
cumulative experience, is often reviewed10,11 without tak-
ing into account the quality of multidisciplinary care avail-
able and the effectiveness of perioperative management.
The PelvEx Collaborative was established to provide
large-volume ‘real world’ data on outcomes after pelvic
exenteration in specialist tertiary referral units that provide
the majority of exenterations for complex rectal cancer in
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their respective regions. The primary aim of the present
study was to investigate trends in surgical outcomes over
time, based on data collated from the PelvExCollaborative.
In addition, outcomes were compared between high- and
low-volume centres within the collaborative.
Methods
This was a multicentre retrospective observational study.
Patients who underwent pelvic exenteration for locally
advanced rectal cancer (LARC) and locally recurrent rectal
cancer (LRRC) from 2004 to mid 2015 were eligible.
International institutions participated in the collaborative,
logging patients in a consecutive series. Each centre is a
tertiary referral unit with specialist expertise. All patients
were discussed routinely at a dedicated cancer multidis-
ciplinary team meeting. A lead investigator from each
participating centre collected data via an institutional
database, and data were subsequently submitted centrally
for analysis. Ethical approval was obtained and data were
processed anonymously.
Before surgery, the diagnosis of rectal cancer was based
on histological assessment and/or radiological imaging.
An agreed data set was completed by all participating
institutions, and data were audited centrally by two
reviewers. Any discrepancies were highlighted and referred
back to submitting institution for clarification.
First, patient characteristics (age, sex, BMI), differences
in bone resection or flap reconstruction (where applicable),
margin status (R classification), length of hospital stay,
30-day major complication rate (Clavien–Dindo grade III
or IV) and mortality rate were assessed for trends over the
time interval from 2004 to 2015. Second, margin status and
extent of resection/reconstruction in high-volume centres
(more than 20 exenterations per year) were compared with
those from low-volume centres (20 or fewer exenterations
annually). Twenty pelvic exenterations was the decided as
the cut-off between high- and low-volume after interro-
gation of the databases, and there was a clear division in
centre volume, with several hospitals routinely performing
more than 20 exenterations per year, whereas most others
showed significant variation in annual volume.
Statistical analysis
Data were analysed using Prism® 7 (GraphPad Software,
San Diego, California, USA). Descriptive analysis was
undertaken to report variable frequencies. Categorical vari-
ables were analysed using the χ2 test, and continuous vari-
ables with the Kruskal–Wallis test. Two-year periods were
compared to assess for significant differences. Reported
intergroup comparisons were considered statistically sig-
nificant at the 5 per cent level (P< 0⋅050).
Results
Some 2472 patients undergoing pelvic exenteration across
26 institutions were included in this study. Male sex was
Table 1 Patient demographics, operative and surgical outcomes following pelvic exenteration for locally advanced rectal cancer,
2004–2015
2004–2005
(n=142)
2006–2007
(n=172)
2008–2009
(n=218)
2010–2011
(n=250)
2012–2013
(n=340)
2014 to mid 2015
(n=180)
Age (years)* 61 64 63 65 63 63
Sex ratio (M : F) 81 : 61 96 : 76 130 : 88 155 : 95 207 : 133 118 : 62
BMI (kg/m2)* 22⋅7 (18⋅4–36⋅1) 23⋅7 (17⋅5–43⋅0) 24⋅1 (16⋅3–44⋅5) 24⋅3 (15⋅3–44⋅3) 24⋅9 (15⋅2–43⋅0) 23 (17⋅5–40⋅1)
Bone resection (%) 5 (3⋅5) 10 (5⋅8) 16 (7⋅3) 20 (8⋅0) 32 (9⋅4) 23 (12⋅8)
Flap used (%) 17 (12⋅0) 35 (20⋅3) 39 (17⋅9) 59 (23⋅6) 97 (28⋅5) 53 (29⋅4)
Duration of surgery (min)* 380 (304–480) 340 (245–459) 350 (270–504) 422 (329–555) 425 (313–568) 506 (408–621)
Blood transfusion (units)* 4 (0–22) 3 (0–23) 2 (0–15) 2 (0–24) 2 (0–31) 2 (0–15)
Margin status
R0 109 (76⋅8) 130 (75⋅6) 186 (85⋅3) 197 (78⋅8) 266 (78⋅2) 150 (83⋅3)
R1 26 (18⋅3) 27 (15⋅7) 27 (12⋅4) 34 (13⋅6) 34 (10⋅0) 24 (13⋅3)
R2 6 (4⋅2) 7 (4⋅1) 3 (1⋅4) 7 (2⋅8) 6 (1⋅8) 1 (0⋅6)
Missing 1 (0⋅7) 8 (4⋅7) 2 (0⋅9) 12 (4⋅8) 34 (10⋅0) 5 (2⋅8)
Length of hospital stay (days) 17 (9–210) 15 (8–120) 14 (7–332) 16 (8–198) 16 (7–104) 18 (6–222)
30-day major complication rate (%) 64 (45⋅1) 68 (39⋅5) 91 (41⋅7) 86 (34⋅4) 106 (31⋅2) 70 (38⋅8)
Surgical reintervention rate (%) 11 (7⋅7) 13 (7⋅6) 22 (10⋅1) 24 (9⋅6) 28 (8⋅2) 13 (7⋅2)
Radiological reintervention rate (%) 11 (7⋅7) 12 (7⋅0) 14 (6⋅4) 16 (6⋅4) 17 (5⋅0) 9 (5⋅0)
30-day mortality rate (%) 2 (1⋅4) 0 (0) 5 (2⋅3) 3 (1⋅2) 7 (2⋅1) 3 (1⋅7)
Values in parentheses are percentages unless indicated otherwise; *values are median (range).
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more common in both LARC and LRRC cohorts (60⋅4
and 63⋅0 per cent respectively). Patient demographics
and operative outcomes are presented in Tables 1 and 2
respectively.
Locally advanced rectal cancer
Some 1302 patients had pelvic exenteration for LARC.
Their median age was 63 (21–90) years and median
BMI was 23⋅9 (14–37⋅4) kg/m2. Rates of bone resec-
tion and flap reconstruction increased from 2004 to 2015
(bone resection: from 3⋅5 to 12⋅8 per cent, P= 0⋅002; flap
reconstruction: from 12⋅0 to 29⋅4 per cent, P= 0⋅001).
There was also an increase in median length of surgery,
from 380 to 506min over the time interval (P< 0⋅001).
Median intraoperative blood transfusion decreased from
4 to 2 units during the time period (P= 0⋅040). There
was no difference in margin rates across the whole cohort
over the 10-year study period (P= 0⋅766), or in length
of hospital stay, 30-day complication, reintervention or
mortality rates.
Table 2 Patient demographics, operative and surgical outcomes following pelvic exenteration for locally recurrent rectal cancer,
2004–2015
2004–2005
(n=188)
2006–2007
(n=165)
2008–2009
(n=208)
2010–2011
(n=239)
2012–2013
(n=251)
2014 to mid 2015
(n=119)
Age (years)* 63 62 63 62 64 62
Sex ratio (M : F) 123 : 65 112 : 53 134 : 74 146 : 93 145 : 106 77 : 42
BMI (kg/m2)* 24⋅1 (15⋅0–36⋅1) 24⋅2 (15⋅1–35⋅5) 25⋅3 (17⋅0–37⋅1) 25⋅8 (17⋅8–35⋅5) 25⋅5 (18⋅0–43⋅1) 24⋅6 (18⋅3–30⋅5)
Bone resection (%) 29 (15⋅4) 52 (31⋅5) 49 (23⋅6) 44 (18⋅4) 54 (21⋅5) 21 (17⋅6)
Flap used (%) 19 (10⋅1) 27 (16⋅4) 50 (24⋅0) 46 (19⋅2) 37 (14⋅7) 29 (24⋅4)
Duration of surgery (min)* 450 (385–575) 524 (421–670) 520 (372–693) 465 (313–644) 480 (356–615) 435 (345–627)
Blood transfusion (units)* 5 (0–28) 5 (0–33) 4 (0–34) 4 (0–34) 3 (0–22) 2⋅5 (0–21)
Margin status
R0 108 (57⋅4) 90 (54⋅5) 111 (53⋅4) 147 (61⋅5) 140 (55⋅8) 66 (55⋅5)
R1 54 (28⋅7) 67 (40⋅6) 77 (37⋅0) 71 (29⋅7) 70 (27⋅9) 28 (23⋅5)
R2 14 (7⋅4) 8 (4⋅8) 20 (9⋅6) 13 (5⋅4) 16 (6⋅4) 8 (6⋅7)
Missing 12 (6⋅4) 0 (0) 0 (0) 8 (3⋅3) 25 (10⋅0) 17 (14⋅3)
Length of hospital stay (days) 17 (8–73) 20 (7–102) 14 (6–189) 14 (7–153) 14 (6–229) 14 (7–78)
30-day major complication rate (%) 84 (44⋅7) 60 (36⋅4) 60 (28⋅8) 76 (31⋅8) 77 (30⋅7) 25 (21⋅0)
Surgical reintervention rate (%) 16 (8⋅5) 13 (7⋅9) 17 (8⋅2) 20 (8⋅4) 15 (6⋅0) 7 (5⋅9)
Radiological reintervention rate (%) 13 (6⋅9) 10 (6⋅1) 11 (5⋅3) 18 (7⋅5) 9 (3⋅6) 5 (4⋅2)
30-day mortality rate (%) 2 (1⋅1) 2 (1⋅2) 2 (1⋅0) 5 (2⋅1) 6 (2⋅4) 3 (2⋅5)
Values in parentheses are percentages unless indicated otherwise; *values are median (range).
Fig. 1 Margin status following pelvic exenteration for locally advanced rectal cancer. a Low-volume centres; b high-volume centres
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Fig. 2 Margin status following pelvic exenteration for locally recurrent rectal cancer. a Low-volume centres; b high-volume centres
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Subgroup analysis showed that bone resection and flap
reconstruction rates increased from 5⋅2 to 19⋅5 per cent
(P= 0⋅002) and from 13⋅4 to 34⋅7 per cent (P= 0⋅001)
in high-volume centres only. Although negative margin
(R0) rates improved in both low- and high-volume centres
across the time interval, only low-volume centres had a sta-
tistically significant improvement (low-volume: from 62⋅5
to 80⋅0 per cent, P= 0⋅001; high-volume: from 83⋅5 to 88⋅4
per cent, P= 0⋅660) (Fig. 1).
Locally recurrent rectal cancer
Some 1170 patients had pelvic exenteration for LRRC.
Their median age was 62 (25–88) years, and median BMI
was 24⋅9 (18⋅0–34⋅5) kg/m2. The rate of bone resection
ranged from 15⋅4 to 31⋅5 per cent (P= 0⋅001), and flap
reconstruction from 10⋅1 to 24⋅4 per cent (P= 0⋅020).
Median length of surgery was 472min, with no change
over time. There was a reduction in median intraoperative
blood transfusion from 5 to 2⋅5 units (P< 0⋅001), but no
differences in length of hospital stay, 30-day complication,
reintervention or mortality rates.
Subgroup analysis found no significant differences in
bone resection or flap reconstruction rates between high-
or low-volume centres over the time. Although not statis-
tically significant, the negative margin rate (R0) increased
in both low- and high-volume centres (low-volume: from
51⋅7 to 60⋅4 per cent, P= 0⋅610; high-volume: from 48⋅6
to 65⋅5 per cent, P= 0⋅100) (Fig. 2).
Discussion
With the movement towards centralization of cancer care
to optimize patient outcomes, evaluation of the trends
in surgical outcomes in centres performing complex rectal
cancer surgery is merited. These PelvEx Collaborative data
show the trend analysis for outcomes following pelvic exen-
teration for LARC and LRRC. Improvements in blood
transfusion and resection margins status were observed
over time. Bone resections to increase radical resections
were performed more often, as were flap reconstructions
in low- and high-volume centres. These findings reflect
improvements in patient selection, better multidisciplinary
input, and improvements in overall perioperative care.
The present study did not identify significant changes in
patient outcomes in the high- versus low-volume centres
over time, suggesting that outcomes are not based solely on
hospital volume. Liu and colleagues12 observed a reduction
in 5-year overall mortality in high-volume referral centres,
but this finding has not been replicated by others13,14.
Differences in surgeon experience, diagnostics, multidis-
ciplinary care, (neo)adjuvant therapies and patient factors
all have complex effects on surgical and patient outcomes.
Case volume per se is not a formal indicator of quality,
but rather is a structural characteristic4, as it appears that
organizational expertise, not increased volume, improves
patient outcomes. In addition, patients who are willing
to travel a long distance to specialist centres tend to be
younger, Caucasian, and in higher socioeconomic classes1.
Elderly patients, or those less able, often remain in local
institutions despite the opportunity to attend specialist
centres15.
A key challenge in assessing volume effect on surgical per-
formance is defining which centre belongs to the high- ver-
sus low-volume category. In the present study, trends across
time were assessed in a group of high- and low-volume
centres, rather than comparing specific centres against one
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 516–520
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another. The authors are aware that not all countries have
regionalized exenteration centres. Some countries have
lower annual volumes of exenteration surgery owing to
population size. Therefore, this study establishes attainable
standards for specialist units, and supports the centraliza-
tion of exenteration surgery to tertiary units that participate
in research and international collaboration.
Major limitations of the study include the absence of
a definition of individual expertise in pelvic exenteration
surgery. Most centres, however, have a number of surgeons
with various levels of experience. Management of advanced
rectal cancer does not rely on a single individual, but
on a surgical unit working together as a team. Owing to
the retrospective nature of the study, it was impossible to
account for confounding variables such as patient factors,
patient selection and diagnostic procedures.
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